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Purpose: The indication of elective neck treatment (ENT) for clinically N0 (cN0) paranasal sinus (PNS) carcinoma remains unclear. 
We aimed to investigate different treatment outcomes regarding ENT and propose optimal recommendations for ENT.
Materials and Methods: We identified patients with cN0 PNS carcinoma who underwent curative-intent treatment between 
1992 and 2015. Survival outcomes and pattern of failure were compared between patients who received ENT and those who did not. 
We sought to identify significant patient or pathologic factors regarding treatment outcomes.
Results: Among 124 patients meeting the inclusion criteria, 40 (32%) received ENT (‘ENT (+) group’) and 84 (68%) did not (‘ENT (−) 
group’). With a median follow-up of 54 months, the 5-year overall survival (OS) was 67%, and the 5-year progression-free survival 
(PFS) was 45%. There was no significant difference between the ENT (+) and ENT (−) groups regarding OS (p = 0.67) and PFS (p = 
0.50). Neither group showed a significantly different pattern of failure, including regional failure (p = 0.91). There was no specific 
benefit, even in the subgroups analysis by tumor site, histologic type, and T stage. Nevertheless, patients who ever had regional and/
or distant failure showed significantly worse prognosis. 
Conclusion: ENT did not significantly affect the survival outcome or pattern of failure in patients with cN0 PNS carcinomas, 
showing that ENT should not be generalized in this group. However, further discussion on the optimal strategy for ENT should 
continue because of the non-negligible regional failure rates and significantly worse prognosis after regional failure events.
Keywords: Paranasal sinus carcinoma, Maxillary sinus carcinoma, Elective neck irradiation, Elective neck dissection, Locoregional 
recurrence, Overall survival
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Introduction
Paranasal sinus (PNS) malignant neoplasms are a rare form 
of head and neck malignancy, accounting for <3% of upper 
aerodigestive tract malignancies [1], with approximately 0.6 
cases per 100,000 people in the United States [2]. PNS cancers 
usually present as locally advanced disease due to the late 
onset of symptoms or the fact that early symptoms resemble 
common sinusitis or rhinitis. As a result, the treatment 
strategy is focused on achieving adequate local control while 
preserving critical nearby anatomic structures [3]. To our 
knowledge, although there are no randomized trials comparing 
different treatment strategies, surgery followed by adjuvant 
radiation is generally accepted as the mainstay of treatment, 
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when resectable [3-5]. 
PNS malignancies have a relatively low incidence of 
regional nodal metastases at initial diagnosis, ranging from 
8.3% to 21.9% [6-8]. This low incidence could be explained 
by a relatively sparse network of lymphatic drainage in the 
maxillary sinus, which consists most of the PNS malignancies. 
This low incidence has led to controversies regarding 
treatment of the neck in patients with clinically node-negative 
(cN0) PNS cancer. Some researchers argue that elective neck 
treatment (ENT) in these patients is unnecessary as no factors 
predictive of regional nodal metastasis are found, making the 
patient selection for ENT difficult [9]. In addition, the absolute 
regional nodal metastasis rate remains relatively low and is 
usually accompanied by local failure, which remains a major 
problem that results in poor prognosis [10]. On the other hand, 
several other retrospective reports insist that ENT is beneficial, 
especially when some adverse features exist [11,12]. Recently, 
a retrospective review of regional failure (RF) in cN0 patients 
with squamous cell carcinoma of the maxillary sinus with 
treatment of primary site only, showed that the rate of occult 
neck metastases was not negligible (14.3%) [13]. As there have 
been no randomized trials regarding this issue, the controversy 
over ENT is ongoing.
Despite considerable debate surrounding this issue, little 
is known about the need for ENT or pattern of failure in PNS 
cancers other than cancer of the maxillary sinus. In light of 
these issues and the ongoing controversy, we conducted 
a retrospective study to investigate different treatment 
outcomes between patients with and without ENT in cN0 PNS 
carcinoma, including sites other than the maxillary sinus and 
pathology other than squamous cell carcinoma. In this study, 
we aimed to propose optimal indications regarding ENT in 
patients with cN0 PNS cancers and investigate the prognosis 
of patients with RF.
Materials and Methods
1. Patient selection
We searched the institutional database for all patients who 
were diagnosed with PNS cancer at Yonsei Cancer Center from 
January 2000 to December 2015. Among 304 patients who 
were identified, those who were initially diagnosed as cN0 
and who received any form of curative-intent treatment with 
a sufficient follow-up period at our institution were eligible. 
Patients with initially node-positive PNS cancers were excluded 
(n = 35); those who had a pathologic diagnosis of melanoma, 
olfactory neuroblastoma, sarcoma, or hematology malignancy 
were also excluded (n = 40). Next, we excluded patients who 
did not have complete medical records or did not receive a 
full course of the initial intended therapy (n = 28). Finally, we 
identified a total of 124 patients diagnosed with cN0 PNS 
cancer who met the eligibility criteria.
2. Data collection
Demographic, histopathologic, and treatment characteristics 
of individual patients were collected from the medical records, 
including age at diagnosis, sex, primary tumor site, histologic 
type, T stage, tumor size, and initial treatment type. All 
patients had an initial evaluation based on either computed 
tomography (CT) or magnetic resonance imaging (MRI). T stage 
was reassessed according to the 7th edition of the American 
Joint Committee on Cancer TNM classification. Patients who 
did not undergo surgery had clinical staging based on CT or 
MRI. Those who underwent surgery had pathologic staging 
based on pathology reports. The initial treatment type included 
information about chemotherapy, surgery, radiotherapy, and 
whether ENT was performed. When surgery was performed, 
surgical pathology characteristics—e.g., status of the resection 
margin (RM), perineural invasion (PNI), and lymphovascular 
invasion (LVI)—were also collected if such reports existed.
Patients who received ENT were defined as those who 
underwent elective neck dissection and/or elective neck 
irradiation. The irradiated dose of the elective neck nodal 
chain was often 45–54 Gy in conventional fractions. At 
our institution, ENT was performed based on the clinician’s 
decision regarding risk factors of nodal metastasis (e.g., 
advanced T stage, histologic subtype, LVI) in each patient.
The main interest of this study was the impact of ENT 
on overall survival (OS), progression-free survival (PFS), and 
pattern of failure. For this purpose, we reviewed the pattern 
of failure and time to relapse of patients. Data of the initial 
failure site, time to relapse, and specific salvage treatment after 
failure were collected. Cumulative failure events in each patient 
were also collected. Failure patterns were classified as local, 
regional, or distant failure (DF). Local failure was defined as any 
failure occurring in structures near the primary tumor site. RF 
was defined as any failure occurring either in the neck nodal 
chains or retropharyngeal space. For RF, the nodal level of the 
failure site was specified according to an established consensus 
guideline [14]. All other failures were categorized as DFs. 
3. Statistical analysis
The characteristics of patients who received ENT and those 
who did not receive ENT were compared via the Pearson 
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χ2 test and independent t-test. OS was defined as the time 
from pathologic diagnosis to death from any cause. PFS was 
defined as the time from pathologic diagnosis to any form of 
disease progression or death. If no events had occurred, the 
patient was censored at the last follow-up date. OS and PFS 
were analyzed according to different prognostic factors using 
the Kaplan-Meier method. Any demographic, pathologic, and 
treatment characteristics relevant to survival outcome were 
investigated using the log-rank test for univariate analysis and 
Cox proportional hazards regression for multivariate analysis. 
We also divided the total patients into subgroups according 
to different tumor sites and histologic subtypes, to determine 
if any subgroups had a different outcome. The OS and PFS of 
patients who had regional or DF were compared with patients 
who did not, to identify differences in survival outcomes. Total 
deaths, total failures, local failures, RFs, and DFs between the 
ENT (+) and ENT (−) groups were compared using the Pearson 
χ2 test. In terms of RF, each nodal recurrence site in patients 
with RF was specified, and common sites of RF were identified. 
Regarding statistical analysis, two-sided significance tests 
were performed, and statistical significance was set at p-value 
≤0.05. Statistical analysis was conducted using IBM SPSS 
version 23.0 (IBM Corp., Armonk, NY, USA).
Results
1. Patient characteristics
As shown in Fig. 1, among 124 patients, 40 (32%) received 
ENT and 84 (68%) did not receive ENT. In the ENT (+) group, 
35 (87.5%) had elective neck irradiation, 4 (10%) had elective 
neck dissection, and 1 patient (2.5%) had both. The baseline 
demographic, histopathologic, and treatment characteristics 
of the ENT (+) and ENT (−) groups are listed in Table 1. The 
median follow-up period was 36 months (range, 2 to 268 
months) and 64 months (range, 3 to 288 months) for the ENT 
(+) and ENT (−) groups, respectively. Overall, most factors 
were not significantly different between the two groups. The 
most common site of PNS cancer was the maxillary sinus 
in both groups—37 of 40 (92%) in the ENT (+) vs. 72 of 84 
(86%) in the ENT (−) group, followed by the ethmoid sinus and 
sphenoid sinus; we found no patients with frontal sinus cancer 
who were eligible for this study. The most common histologic 
type was squamous cell carcinoma—29 of 40 (73%) in the 
ENT (+) vs. 53 of 84 (63%) in the ENT (−) group. No significant 
difference in T stage, tumor size, or pathologic factors, 
including RM, LVI, or PNI, between the groups was noted. In 
terms of treatment modalities, the treatment scheme for all 
cN0
PNS cancer
(2000-2015)
(n = 124)
ENT (-)
(n = 84,
68%)
ENT (+)
(n = 40,
32%)
Neck irradiation
(n = 35)
Neck irradiation and
dissection
(n = 1)
Neck dissection
(n = 4)
Fig. 1. Treatment flow chart of patients with clinically N0 (cN0) paranasal sinus (PNS) cancer, with or without elective neck treatment 
(ENT).
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Table 1. Patient and tumor characteristics 
Characteristic
ENTa)
p-value
Yes                                                 No
Follow-up period (mo)
Age (yr)
Sex
  Male
  Female
Diagnosis
  Maxillary
  Ethmoid
  Sphenoid
Histologic type
  Squamous cell carcinoma
  Adenocarcinoma
  Adenoid cystic carcinoma
  Others
Treatment type
  Neoadjuvant RT (+/- CTx) + Op
  Neoadjuvant CTx + Op
  Op +/- adjuvant CTx
  Op + adjuvant RT (+/- CTx)
  Definitive RT (+/- CTx)
Initial T stage
  T2
  T3
  T4
Tumor size (cm)
Op
  Yes
  No
RM
  Positive (<1 mm)
  Close (1–5 mm)
  Negative
PNI
  Yes
  No
LVI
  Yes
  No
CTx
  Yes
  No
Neoadjuvant CTx
  Yes
  No
Concurrent/adjuvant CTx
  Yes
 No
RT (primary mass ± node)
  Yes
  No
 36 (2–268)
 60 (40–77)
 27 (68)
 13 (32)
 37 (92)
 3 (8)
 0 (0)
 29 (73)
 0 (0)
 8 (20)
 3 (7)
 2 (5)
 1 (3)
 0 (0)
 26 (64)
 11 (28)
 3 (8)
 16 (40)
 21 (52)
 4.5 (0.8–8.5)
 29 (72)
 11 (28)
 14 (67)
 2 (10)
 5 (23)
 4 (31)
 9 (69)
 4 (31)
 9 (69)
 21 (52)
 19 (48)
 1 (3)
 39 (97)
 20 (50)
 20 (50)
 39 (98)
 1 (2)
 64 (3–288)
 55 (33–82)
 58 (69)
 26 (31)
 72 (86)
 10 (12)
 2 (2)
 53 (63)
 5 (6)
 15 (18)
 11 (13)
 5 (6)
 11 (13)
 1 (1)
 52 (62)
 15 (18)
 10 (12)
 42 (50)
 32 (38)
 4.0 (2.5–7.5)
 64 (76)
 20 (24)
 30 (58)
 5 (10)
 17 (32)
 5 (50)
 5 (50)
 0 (0)
 6 (100)
 23 (27)
 61 (73)
 9 (11)
 75 (89
 20 (24)
 64 (76)
 71 (85)
 13 (15)
0.14
0.86
0.45
0.31
0.3
0.3
0.16
0.66
0.74
0.35
0.13
0.01
0.12
<0.01
0.03
Continued on the next page.
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patients was classified into five major categories: neoadjuvant 
radiotherapy (±chemotherapy) + operation (Op), neoadjuvant 
chemotherapy + Op, Op ± adjuvant chemotherapy, Op 
+ adjuvant radiotherapy (±chemotherapy), or definitive 
radiotherapy (±chemotherapy). Chemotherapy was performed 
more often in the ENT (+) group (21 of 40; 52%) than in the 
ENT (−) group (23 of 84; 27%) Radiotherapy for the primary 
mass was also performed more often in the ENT (+) than in 
the ENT (−) group. A difference in radiotherapy modality was 
noted, with intensity-modulated radiotherapy used more 
frequently in the ENT (+) group (35 of 40; 88%) than in the 
ENT (−) group (18 of 84; 21%). 
2. Treatment outcomes and prognostic factors
After a median follow-up period of 54 months, a total of 47 
deaths and 75 failures occurred in all patients. The 3-year 
and 5-year OS rates were 74% and 67%, respectively, in the 
total patients; the 3-year and 5-year PFS rates were 55% and 
45%, respectively (Fig. 2). In the total patients, local failure 
occurred in 52 patients (42%), RF occurred in 21 patients (17%), 
and DF occurred in 34 patients (27%). We also investigated 
whether any significant demographic, histopathologic, or 
treatment factors showed prognostic values regarding OS and 
PFS. On univariate analysis of OS, diagnosis of the primary 
site (categorized as ethmoid sinus vs. other) was the only 
significant factor (p < 0.01). RM (categorized as negative 
vs. close or positive margin, p = 0.12) and the addition of 
chemotherapy (p = 0.08) showed marginal significance. 
After multivariate analysis concerning the above factors 
with elective neck treatment, no factors showed significant 
prognostic values. Univariate analysis of PFS showed similar 
results. Diagnosis of the primary site (p = 0.05) and RM (p 
= 0.02) were significant factors for PFS, and the addition of 
chemotherapy (p = 0.06) showed marginal significance. On 
multivariate analysis of PFS with the abovementioned factors, 
RM was the only significant factor (p = 0.02) (Table 2).
3. Impact of ENT on survival and pattern of failure
Regarding OS, the addition of ENT did not show statistically 
significant improvement (p = 0.67). The 3-year and 5-year OS 
rates were 72% and 64% in the ENT (+) group and 74% and 
69% in the ENT (−) group, respectively (Fig. 3A). The addition 
of ENT also did not show significant improvement in PFS (p 
= 0.50). The 3-year and 5-year PFS rates were 59% and 33% 
in the ENT (+) group, and 54% and 48% in the ENT (−) group, 
respectively (Fig. 3B). 
Table 1. Continued 
Characteristic
ENTa)
p-value
Yes                                                 No
RT aim
  Definitive
  Adjuvant or neoadjuvant
RT total dose (Gy)
RT modality
  3D-CRT
  IMRT
 11 (28)
 28 (72)
 63.6 (42.0–73.6)
 5 (12)
 35 (88)
 16 (23)
 55 (77)
 63.0 (39.6–77.4)
 66 (79)
 18 (21)
0.54
<0.01
Values are presented as median (range) or number (%).
ENT, elective neck treatment; Op, operation; CTx, chemotherapy; RT, radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy; 
IMRT, intensity-modulated radiotherapy; RM, resection margin; PNI, perineural invasion; LVI, lymphovascular invasion.
a)Elective neck dissection and/or neck irradiation.
Fig. 2. Overall survival (OS) and progression-free survival (PFS) 
rates in all patients with clinically N0 paranasal sinus cancer (n = 
124).
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When the ENT (+) and ENT (−) groups were compared 
according to different failure patterns, no statistically 
significant difference was noted between the two groups, as 
shown in Table 3. RF occurred in 7 of 40 (18%) patients in 
the ENT (+) group, and 14 of 84 (17%) patients in the ENT 
(−) group (p = 0.91). Details of patients who had RFs without 
ENT are specified in Table 4. Among these patients, the most 
common site of the primary tumor was the maxillary sinus 
(10 of 14; 71%), followed by the ethmoid sinus and sphenoid 
sinus. The most frequent histologic subtype was squamous 
cell carcinoma (9 of 14; 64%). RF was most commonly noted 
in ipsilateral level I or II, in 10 of 14 patients. The RF patterns 
of this group are schematized in Fig. 4A and 4B. In the ENT 
(+) group, 4 of 7 (57%) RFs were in-field failures after elective 
neck irradiation, 1 of 7 (14%) RF was failure in the electively 
dissected neck, while 2 of 7 (29%) RFs were out-field failures 
in the contralateral neck after elective neck irradiation. There 
was no marginal failure. Radiation dose of in-field failures 
were 44, 46, 48, and 51 Gy for each failures.
4. Survival outcomes in patients with DF and/or RF
We investigated survival outcomes with respect to DFs and/or 
RFs. Between patients who had DFs (‘DF (+) group’, n = 34) and 
those who did not (‘DF (−) group’, n = 90), significantly worse 
survival outcome in all survival endpoints was noted in the 
failure-positive group (Fig. 5A). The 5-year OS and PFS rates 
were 51% and 23% in the DF (+) group and 74% and 55% in 
the DF (−) group, respectively (p < 0.01). Among patients who 
had RFs (‘RF (+) group’, n=21) and those who did not (‘RF (−) 
group’, n = 103), we found similar results when OS and PFS 
were compared between the two groups (Fig. 5B). The 5-year 
OS and PFS rates were 41% and 14%, respectively, in the RF 
(+) group, in contrast to 74% and 52%, respectively, in the 
RF (−) group (p < 0.01). In the RF (+) group, 13 of 21 patients 
(62%) had local failure preceding RF, and a total of 14 deaths 
occurred. Of these 14 deaths, 6 were due to sequential distant Ta
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Table 3. Patterns of failure according to ENT
ENT
p-value
Yes No
Total death
Total failure
Local failure
Regional failure
Distant failure
 13 (33)
 23 (58)
 16 (40)
 7 (18)
 11 (28)
 34 (40)
 52 (62)
 36 (43)
 14 (17)
 23 (27)
0.39
0.64
0.76
0.91
0.99
Values are presented as number (%).
ENT, elective neck treatment.
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metastasis causing organ failure, such as of the lung and liver. 
Five deaths were owing to local progression combined with 
regional metastasis leading to invasion of critical organs, such 
as the brain and spinal cord.
Fig. 3. Comparison of Kaplan-Meier survival curves regarding elective neck treatment (ENT): overall survival (A) and progression-free
survival (B).
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Fig. 4. Regional failure pattern in the ENT (−) group: ipsilateral neck (A) and contralateral neck (B).
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5. Subgroup analysis of OS and PFS by tumor site, 
histologic type, and T stage
We performed subgroup analysis of OS and PFS by tumor site, 
histologic type, and T stage. Table 5 summarizes the impact 
of ENT on OS and PFS in each subgroup. Of the 109 patients 
with maxillary sinus cancer, 41 (38%) were T4 stage. Regarding 
pathologic characteristics for which specific information was 
available, 71% (47 of 69) of patients had close or positive RM, 
41% (9 of 22) were PNI positive, and 22% (4 of 18) were LVI 
positive. In this subgroup, 37 patients (34%) received ENT. The 
5-year OS and PFS rates were 67% and 33% in the ENT (+) 
group and 76% and 53% in the ENT (−) group, respectively 
(all p > 0.05) (Fig. 6). The RF rates among these patients were 
81% in the ENT (+) group and 86% in the ENT (−) group (p 
= 0.49). Among 15 patients with ethmoid sinus or sphenoid 
sinus cancer, 3 patients (20%) received ENT. The 5-year OS 
rates—33% in the ENT (+) vs. 28% in the ENT (−) group—and 
PFS rates—33% in the ENT (+) vs. 18% in the ENT (−) group—
were also not improved by ENT (all p > 0.05). The RF rates in 
this group were 0% in the ENT (+) group and 33% in the ENT (−) 
group (p = 0.24). 
Among 82 patients with squamous cell carcinoma, 41 
(50%) had T4 stage disease. For patients in whom specific 
pathologic characteristics were available, 61% (25 of 41) had 
close or positive RM, 0% (0 of 11) was PNI positive, and 9% (1 
of 11) were LVI positive. In this subgroup, 29 patients (35%) 
received ENT. The 5-year OS and PFS rates were 61% and 39% 
in the ENT (+) group and 63% and 44% in the ENT (−) group, 
respectively (all p > 0.05) (Fig. 7). The RF rates in this group 
were 86% in the ENT (+) group and 83% in the ENT (−) group 
Fig. 5. Comparison of Kaplan-Meier survival curves of overall 
survival with respect to distant failure (A) and regional failure (B). 
A B
Fig. 6. Comparison of Kaplan-Meier survival curves of subgroup of maxillary sinus: overall survival (A) and progression-free survival (B). 
ENT, elective neck treatment.
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(p = 0.71). In 23 patients with adenoid cystic carcinoma, 15 
(35%) patients received ENT. 5-year OS rate was not improved 
by ENT—63% in the ENT (+) vs. 86% in the ENT (−) group, p 
= 0.15, while 5-year PFS rate showed statistically significant 
difference—0% in the ENT (+) vs. 65% in the ENT (−) group, 
p = 0.03. No significant difference in RF rates were noted 
according to ENT—25% in the ENT (+) vs. 20% in the ENT (−) 
group, p = 0.78. Among 5 patients with adenocarcinoma, all 
patients didn’t receive ENT. The 5-year OS and PFS rates were 
75% and 53%, respectively. No patient had regional recurrence 
in this subgroup. In subgroup analysis excluding adenoid cystic 
carcinoma from the total patient group, no different outcomes 
or significant improvement in survival by ENT was noted.
Of the 71 patients staged as T2 or T3, 44 (62%) had 
squamous cell carcinoma. For patients in whom specific 
pathologic characteristics were available, 69% (34 of 49) had 
close or positive RM, 39% (5 of 13) were PNI positive, and 27% 
(3 of 11) were LVI positive. In this subgroup, 19 patients (27%) 
received ENT. The 5-year OS rates showed no statistically 
significant by ENT—61% in the ENT (+) vs. 78% in the ENT (−) 
group, p = 0.41, while 5-year PFS rates showed significant 
difference—25% in the ENT (+) vs. 54% in the ENT (−) group, 
p = 0.04. The RF rates in this group was 32% in the ENT (+) 
group and 13% in the ENT (−) group (p = 0.08). Among 53 
patients with T4 stage, 21 patients (40%) received ENT. The 
5-year OS and PFS rates were 67% and 40% in the ENT (+) 
group and 52% and 38% in the ENT (−) group (all p > 0.05). 
The RF rates in this group was 5% in the ENT (+) group and 
22% in the ENT (−) group (p = 0.09). 
Discussion and Conclusion
In the present study, we showed that ENT has no benefit 
regarding survival rates or failure patterns, including RF rates, 
in patients with cN0 PNS cancer. RM was the only significant 
factor for survival rate; however, the addition of ENT did not 
have a significant impact on OS, PFS, or pattern of failure. 
This result was consistent in the subgroup analysis by tumor 
site, histologic type, and T stage. However, the RF (+) group 
showed dismal prognosis, similar to that of the DF (+) group, 
mainly due to sequential distant metastasis or combined local 
progression, suggesting the need for further investigation of 
proper regional management.
The efficacy of ENT in PNS cancer has been a controversial 
issue for many years. As a result, there has been no ‘gold 
standard’ regarding ENT in patients with cN0 PNS cancer. Our 
results, showing no significant benefits of ENT, are consistent 
with those of several studies stating that ENT is unnecessary 
in patients with cN0 PNS cancer. The clinical significance of 
ENT has been questioned by several researchers owing to the 
Fig. 7. Comparison of Kaplan-Meier survival curves of subgroup of squamous cell carcinoma: overall survival (A) and progression-free 
survival (B). ENT, elective neck treatment.
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relatively low incidence of RF compared with local failure. Kim 
et al. [10] analyzed 116 patients with maxillary sinus squamous 
cell carcinoma. During follow-up, the RF rate (19%) was far 
lower than the local failure rate (68%). Park et al. [15] also 
recently reported that the rate of occult cervical metastasis in 
maxillary squamous cell carcinoma was not sufficiently high 
(15%) to routinely recommend elective neck dissection. The 
RF rates in previous studies are fairly consistent with the RF 
rate in our study (17%). Moreover, previous researchers have 
pointed out that no subgroup of patients at higher risk of RF 
has been identified [9]. Our findings, showing no benefit of 
ENT in the subgroup analysis by tumor site, histologic type and 
T stage, support this idea. In addition to these findings, our 
study showed that ENT had no benefit with respect to OS, PFS, 
or RF rates. Also, pattern of failure revealed that RF mostly 
occurred in maxillary sinus cancer or squamous cell carcinoma 
when ENT was not performed. The most common RF site was 
ipsilateral neck level I or II. We believe that these findings could 
provide useful information to radiation oncologists when they 
need to decide whether to perform elective neck irradiation or 
not in cN0 PNS cancer patients. In addition, to our knowledge, 
this study is one of the few studies including a considerable 
number of patients that directly compares the efficacy of ENT 
with respect to survival and pattern of failure in patients with 
cN0 PNS cancer. 
However, our results contradict some previous arguments 
made in former studies. Jiang et al. [12] and Joosten et al. [13] 
claimed that elective neck irradiation should be considered in 
patients with squamous cell and undifferentiated carcinoma or 
advanced T stage because the RF rate was high (19%–38%) in 
these patients. Recently, Jeon et al. [16] reported that ENT was 
effective in preventing RF in squamous cell and undifferentiated 
carcinoma of the maxillary sinus with posterior wall invasion. 
Among 8 patients who received ENT in their study, only 1 
patient had RF, whereas 9 of 47 patients who received ENT and 
were initially cN0 experienced RF in our study, showing that 
ENT might have a considerable effect on survival.
The reason that the results of our study conflict with those 
of other studies could be explained in several ways. First, the 
patient subset in our study differs considerably from that 
of other studies [11-13,16,17]. We enrolled all patients with 
PNS cancer, including those with ethmoid sinus and sphenoid 
sinus cancers. We also included histologic subtypes other than 
squamous cell carcinoma, to determine the efficacy of ENT in 
all PNS cancers. Although our subgroup analysis by tumor site, 
histologic type, and T stage did not show positive impact of 
ENT on OS and PFS, the number of patients in each subgroup 
might have been insufficient to achieve statistically significant 
difference since other studies showed clinical benefit in 
specific patient subsets as aforementioned. Also, the possibility 
that other factors such as surgical pathology characteristics 
(e.g., RM, LVI, PNI) could affect survival outcomes cannot 
be excluded [13,18]. Second, previous studies [12,17] might 
have included patients that would currently be diagnosed 
as clinically node positive due to advancements in imaging 
techniques. Studies conducted before the widespread use of 
CT or MRI relied on clinical nodal staging based on physical 
examination or plain radiography, which likely missed some 
patients that would have been diagnosed as node positive 
using modern imaging. On the other hand, at our institution, 
CT has routinely been used for initial staging in head and 
neck cancer patients, and MRI was added to the routine 
staging process after the mid-2000s. In other words, our 
results should be accepted on the basis of precise radiologic 
evaluation. Lastly, the proportion of patients who underwent 
chemotherapy differed from that of other groups. In our study, 
35% of the total patients had chemotherapy. This differs 
substantially from other studies specifying the proportion 
of patients that received chemotherapy (58%–81%) [16,19]. 
Although our study did not show a significant effect of 
chemotherapy on survival, we should nevertheless consider the 
impact of chemotherapy, as some reports insist that survival or 
RF rates could be affected by chemotherapy [16,19,20]. 
In our study, univariate analysis of PFS showed that primary 
site and RM were significant factors whereas chemotherapy 
showed marginal significance. After multivariate analysis with 
ENT and the above factors, RM was the only significant factor 
(p = 0.02). Regarding OS, although RM did show prognostic 
marginal significance in univariate analysis (p = 0.12), no 
factors showed significant prognostic values in multivariate 
analysis. These findings are in line with previous findings that 
complete surgical resection of the primary tumor is essential 
for long-term survival in this type of cancer [3,10,19,21]. Local 
control is the key treatment factor in patients with PNS cancer 
because of the critical organs located nearby, such as the 
brain, brainstem, optic nerve, inner ear, and so forth. Repetitive 
local failures may unfavorably affect patient quality of life and 
may make local control very difficult. Furthermore, according 
to a report by Kim et al. [10], local recurrence precedes most 
nodal failures, again highlighting the importance of local 
control. Similarly, in our study, 13 of 21 (62%) patients with 
RF had local failure preceding RF. Especially in the ENT (+) 
group, all in-field failures had local failure preceding RF, 
or simultaneously with RF. These local failures might have 
Won Hee Le, et al
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contributed to the relatively high in-field failure rate despite 
that adequate elective irradiation dose of 44-51 Gy was 
given. Moreover, patients who underwent chemotherapy had 
worse prognosis in univariate analysis than patients who did 
not receive chemotherapy. This indicates that this patient 
subset featured various risk factors at initial diagnosis or after 
surgery, which led physicians to add chemotherapy. After 
multivariate analysis, chemotherapy showed no prognostic 
significance. 
In subgroup analysis, no subgroups were identified to 
have benefit from ENT in terms of survival outcomes or 
regional failure rates. All tumor sites showed no statistically 
significant differences according to addition of ENT in OS 
and PFS. All histologic subtypes (squamous cell carcinoma, 
adenocarcinoma, adenoid cystic carcinoma) and T stages (T2-
3, T4 stage) also mostly showed similar results in OS and PFS. 
However, this result should be carefully interpreted. It is highly 
likely that patients with known risk factors of locoregional 
recurrences would have received ENT (+), which could have 
resulted in bias in this retrospective study. The finding of worse 
PFS even with ENT in subgroup of adenoid cystic carcinoma 
and T2-3 stage might be explained by this bias. Although 
statistically significant difference of patient and tumor 
characteristics between the ENT (+) and the ENT (−) group in 
each subgroup was not found due to small number of patients, 
it is possible that the effect of ENT on survival outcomes and 
RF rates was masked by this bias. 
On the other hand, despite the inefficacy of ENT on survival 
outcomes and pattern of failure shown in our study, patients 
with RF clearly had dismal prognosis compared with patients 
who did not have RF. The 5-year OS and PFS rates were 
41% and 14%, respectively, in the RF (+) group, which were 
significantly worse than those of the RF (−) group (p < 0.01). 
A notable point was that the survival outcomes in the RF (+) 
group were similar to those in the DF (+) group. The worse 
prognosis of patients with RF than that of patients without 
RF has been previously reported in several studies. Paulino et 
al. [17] found a statistically significant difference in OS rates 
between the RF (+) and RF (−) groups. A similar pattern was 
also discovered in a retrospective review of maxillary sinus 
cancer, showing 5-year survival of 37% in patients with neck 
control, and 0% in patients with neck relapse [11]. Another 
study also pointed out that the prognosis of RF patients was 
similar to that of patients with T4N0 disease [10]. According to 
our study, patients who experienced RF mostly died of organ 
failure caused by subsequent distant metastasis or combined 
local disease progression. The dismal prognosis of patients 
with RF and possible bias in our study emphasizes that efforts 
should continue to find a specific patient subgroup in this 
disease that would benefit from ENT, to improve survival in 
this disease, yet it has not been found in present study.
Our study is a retrospective review, and thus has 
innate limitations. First, some specific surgical pathology 
characteristics (e.g., RM, PNI, LVI status) were missing. Among 
patients who underwent surgery, many previous pathology 
reports have lacked information on those characteristics. As a 
result, analysis based on specific pathology characteristics was 
limited. In addition, PNS cancers other than maxillary sinus 
(ethmoid sinus, n = 13; sphenoid sinus, n = 2) or pathology 
other than squamous cell carcinoma (adenocarcinoma, n = 5; 
adenoid cystic carcinoma, n = 23) might have been insufficient 
in number to show any statistically significant difference 
in subgroup analysis. However, although the number of 
patients was small, subgroup analysis with specific tumor 
site or pathology, including analysis excluding adenoid cystic 
carcinoma, did not show different outcomes. Also, the strength 
of the present study is quite clear in that it is the one of the 
few studies directly comparing the efficacy of ENT in patients 
with PNS cancer whose initial clinical diagnosis was N0, with 
respect to survival and pattern of failure. 
In conclusion, our retrospective review indicated that ENT 
might have no apparent benefit regarding OS, PFS, pattern of 
failure, as well as RF rates, in patients with cN0 PNS cancer. 
ENT should not be generalized to all patients with cN0 PNS 
cancer. This treatment should only be considered carefully in 
patients with many adverse features after multidisciplinary 
discussion. Instead, local control should be considered first; 
our result showing that RM status is a statistically significant 
prognostic factor for survival supports this idea. However, 
the dismal prognosis of patients after RF and the limitations 
of this retrospective study emphasize the need for further 
research with larger cohorts, to identify the specific patient 
subset that would benefit from ENT. 
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